BioCryst Pharmaceuticals (BCRX) Posts Wider than Expected Q1 Loss
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $10.45 -2.52%
Revenue Growth %: +13.7%
Financial Fact:
Research and development: 14.11M
Today's EPS Names:
CCEL, FEIM, PLG, More
Revenue Growth %: +13.7%
Financial Fact:
Research and development: 14.11M
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
BioCryst Pharmaceuticals (Nasdaq: BCRX) reported Q1 loss of ($0.29), $0.09 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $17.04 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioCryst Pharma (BCRX) PT Raised to $14 at RBC Capital
- Northern Technologies (NTIC) Misses Q3 EPS by 12c
- Kura Sushi (KRUS) Tops Q3 EPS by 3c; offers outlook
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
